TNGX Tango Therapeutics, Inc.

NASDAQ
$24.92

Tango Therapeutics, Inc. (TNGX) is expected to report earnings on November 9, 2026, after the market close. The consensus earnings estimate is a loss of $0.34 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -7.9% since its last earnings release on August 11, 2026.

Tango Therapeutics Missed Consensus Estimates
Tuesday, August 11, 2026 · 7:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 9
Monday · After Close
Earnings Whisper
-
vs ($0.34)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $24.07

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Tango Therapeutics, Inc.

Tango Therapeutics Inc. is a biotechnology company. It focused on discovering and delivering precision cancer medicines. Tango Therapeutics Inc., formerly known as BCTG Acquisition Corp., is based in CAMBRIDGE, Mass.

Sector

Healthcare

Industry

Biotechnology

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.